Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

MLA

Blackwell, Kimberly L., et al. “Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-Positive Breast Cancer: A Phase I/II Study.” Clinical Breast Cancer, vol. 19, no. 2, Apr. 2019, p. 97. EBSCOhost, https://doi.org/10.1016/j.clbc.2018.12.011.

APA

Blackwell, K. L., Zaman, K., Qin, S., Tkaczuk, K. H. R., Campone, M., Hunt, D., Bryce, R., & Goldstein, L. J. (2019). Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical Breast Cancer, 19(2), 97. https://doi.org/10.1016/j.clbc.2018.12.011

Chicago

Blackwell, Kimberly L, Khalil Zaman, Shukui Qin, Katherine H R Tkaczuk, Mario Campone, Daniel Hunt, Richard Bryce, and Lori J Goldstein. 2019. “Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-Positive Breast Cancer: A Phase I/II Study.” Clinical Breast Cancer 19 (2): 97. doi:10.1016/j.clbc.2018.12.011.